Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02948231
Other study ID # CL-133
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 25, 2016
Est. completion date February 2022

Study information

Verified date February 2022
Source Mitralix
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Mitral Regurgitation. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.


Description:

The study is designed to clinically demonstrate device acute safety (Primary Endpoint) along with longer FU device safety and effectiveness evaluation (Secondary Endpoint). The main objectives of the study are : - Evaluate the Acute safety of the implanted Mistral device post procedure and at 30 day follow up period. - Evaluate the long term Safety of the device (3 and 6 months follow up). - Demonstrate effectiveness of the Mistral device in improving MR. Primary endpoints: • Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event. At discharge and 30 days. Secondary endpoints: - • Safety: Safety at 3 and 6 months. Rate of SAEs and device related SAEs at 3, 6 and 12months. - Effectiveness: MR reduction post-procedure, at discharge and 30 days, 3 and 6 and 12 months. Improved NYHA class and 6MWT distance at 30 days, 3 and 6 and 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date February 2022
Est. primary completion date January 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is willing and able to comply with all required follow-up evaluations - Genders eligible for the study: Both genders - Subject has functional MR of grade 3+ or more - Subject has left ventricular ejection fraction (LVEF) >20 % and < 40%. - No contraindications to trans-septal puncture - Subject is of functional class 3 or more (NYHA) - The subject is high risk to undergo MV surgery. - Subject is excluded from other standard of care procedures as determined by center heart team. - Patients with femoral veins enabling catheterization with 12Fr catheters - Life expectancy = 1 year Exclusion Criteria: - Mitral Stenosis = moderate - Aortic Stenosis/Insufficiency > moderate - Subvalvular calcification or calcification of the chordae. - Subject has a prosthesis valve in the mitral position - Transcatheter aortic valve replacement (TAVR) within 30 days prior to subject registration - Subject has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months. - Subject has a history of a myocardial infarction (MI) in the past 3 months - Subject refuses blood transfusion or surgical valve replacement. - Subject has had a percutaneous interventional or other invasive cardiac or peripheral procedure = 7 days of the index procedure - Subject has a history of, or has active endocarditis - Subject has echocardiographic evidence of intra-cardiac mass, thrombus, vegetation or soft-mobile deposits - Subject is in acute pulmonary edema. - Subject has hemodynamic instability requiring inotropic or mechanical support. - Subject has a known hypersensitivity or contraindication to anticoagulant or antiplatelet medication - Subject has renal insufficiency as evidenced by a serum Creatinine > 3.0mg/dL. - Subject has ongoing infection or sepsis - Subject has blood dyscrasias (leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy) - Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 3 months prior to the index procedure - Subject requires emergency surgery for any reason - Subject has a known allergy to Nitinol alloys, 316L\304 stainless steel. - Pregnant or lactating women. - Patients being dependent upon the sponsor or upon the investigator or upon the investigational site. - Subject has a known contrast media allergy - Presence of high degree atrio-ventricular block (2nd or 3rd degree A-V block), or the presence of tri-fascicular block - According to investigator on site the patient is suffering from a severe end stage disease (e.g. malignancy, severe pulmonary disease, liver disease, renal failure) and has a life expectancy of less than 1 year.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Mistral implantation
Mistral Implant is implanted in the Mitral valve

Locations

Country Name City State
Belgium ZNA Middelheim Antwerpen

Sponsors (1)

Lead Sponsor Collaborator
Mitralix

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event. Until hospital discharge - up to 5 days post procedure day
Primary Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event. at 30 days post-procedure
Secondary Safety: Rate of device related SAE at 3 months post procedure
Secondary Safety: Rate of device related SAE at 6 months post procedure
Secondary Safety: Rate of device related SAE at 12 months post procedure
Secondary Effectiveness: MR Grade reduction. Post procedure (1 hour after implant device has been implanted)
Secondary Effectiveness: MR Grade reduction. Until hospital discharge - up to 5 days post procedure day
Secondary Effectiveness: MR Grade reduction. at 30 days post procedure
Secondary Effectiveness: MR Grade reduction. at 3 months post procedure
Secondary Effectiveness: MR Grade reduction. at 6 months post procedure
Secondary Effectiveness: MR Grade reduction. at 12 months post procedure
Secondary Effectiveness: NYHA class (categorization of heart failure extent). Post procedure (1 hour after implant device has been implanted)
Secondary Effectiveness: NYHA class (categorization of heart failure extent) Until hospital discharge - up to 5 days post procedure day
Secondary Effectiveness: NYHA class (categorization of heart failure extent) at 30 days post procedure
Secondary Effectiveness: NYHA class (categorization of heart failure extent) at 3 months post procedure
Secondary Effectiveness: NYHA class (categorization of heart failure extent) at 6 months post procedure
Secondary Effectiveness: NYHA class (categorization of heart failure extent) at 12 months post procedure
Secondary Effectiveness: 6MWT distance. Post procedure (1 hour after implant device has been implanted)
Secondary Effectiveness: 6MWT distance. Until hospital discharge - up to 5 days post procedure day
Secondary Effectiveness: 6MWT distance. at 30 days post procedure
Secondary Effectiveness: 6MWT distance. at 3 months post procedure
Secondary Effectiveness: 6MWT distance. at 6 months post procedure
Secondary Effectiveness: 6MWT distance. at 12 months post procedure
See also
  Status Clinical Trial Phase
Completed NCT02520310 - AVJ-514 Japan Trial N/A
Not yet recruiting NCT06465745 - AltaValve Pivotal Trial N/A
Completed NCT02355418 - The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
Recruiting NCT04577248 - The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry
Recruiting NCT03242642 - Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. N/A
Recruiting NCT02961647 - Hemodynamic Stress Test in Severe Mitral Regurgitation (HEMI) N/A
Active, not recruiting NCT02302872 - Treatment of Heart Failure and Associated Functional Mitral Valve Regurgitation N/A
Completed NCT01777815 - Safety and Performance Study of the NeoChord Device N/A
Withdrawn NCT00428103 - Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy N/A
Completed NCT04351984 - Transcatheter Mitral Valvuloplasty Pilot Study
Withdrawn NCT02722551 - CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study Phase 1/Phase 2
Active, not recruiting NCT02321514 - Expanded Clinical Study of the Tendyne Mitral Valve System N/A
Recruiting NCT02245763 - STS/ACC TVT Registry Mitral Module
Active, not recruiting NCT01740583 - Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation N/A
Completed NCT00800046 - A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study N/A
Completed NCT00415701 - Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Phase 4
Recruiting NCT03908983 - OPtimisation of Surgical Repair for Treating Insufficiency of the MItral Valve - Safety and Effectiveness Evaluation N/A
Active, not recruiting NCT04818502 - Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
Terminated NCT03285724 - Safety and Performance Study of the Harpoon Mitral Valve Repair System N/A
Recruiting NCT04195984 - Mi-thos® Transcatheter Mitral Valve Replacement Study N/A